Welcome
Support Centre
18 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Study of practice pharmacist-led management of long-term pain
ISRCTN ISRCTN06131530
ClinicalTrials.gov identifier
Public title Study of practice pharmacist-led management of long-term pain
Scientific title A pilot randomised controlled trial of general practice-based, pharmacist-led, management of chronic pain
Acronym PIPPC
Serial number at source G0701769; pRGF/106/09
Study hypothesis We wish to conduct a definitive trial that tests whether pharmacists advice or pharmacists advice and prescribing will lead to better patient functioning and/or better pain control than standard care. This exploratory randomised controlled trial (RCT) will support the development and test the feasibility of conducting a future large multi-centred RCT to evaluate practice-based, pharmacist-led management of chronic pain in primary care.
Ethics approval North of Scotland Research Ethics Service, Committee 1 (NoSRES) approved on the 30th November 2009 (ref: 09/S0801/107)
Study design Exploratory randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Chronic pain
Participants - inclusion criteria 1. GP practices: any general practice with an existing practice pharmacist service
2. Pharmacists: a registered prescriber with evidence of appropriate professional indemnity cover
3. Patients:
3.1. Male and female patients
3.2. Aged over 18 years old
3.3. Chronic pain (defined as pain lasting more than 13 weeks)
3.4. Receiving regular prescribed medication for pain
Participants - exclusion criteria 1. GP practices: no existing practice pharmacists
2. Pharmacists: not a registered prescriber or does not have evidence of appropriate professional indemnity cover
3. Patients:
3.1. Under 18 years old
3.2. Not experiencing chronic pain
3.3. Concomitant severe mental health problems
3.4. Terminal illness
3.5. Recent bereavement
3.6. Known alcohol or drug addiction
3.7. Unable to give informed consent
3.8. Malignant pain
3.9. Recent participation in research
3.10. Any other reason at the discretion of the GP for whom the intervention is considered inappropriate
Anticipated start date 04/01/2010
Anticipated end date 01/11/2010
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants Patients: 216; GP practices: 6; pharmacists: 6
Interventions There are three arms in this study:
1. Pharmacist review: pharmacist medication review with recommendations for changes in pain medication made to GPs for indirect implementation
2. Pharmacist prescribing: pharmacist medication review with pain management recommendations implemented directly by pharmacist at a face-to-face consultation with the patient
3. Standard care provided by GP (control)

Total duration of treatment for pharmacist prescribing arm is 31 minutes. Follow-up may take place between 2 - 4 weeks after initial consultation and take place at maximum twice a month for the 6-month follow-up period of the study. The follow-up period for all arms is 6 months.
Primary outcome measure(s) Information from this pilot RCT will be used to inform final selection of a single primary outcome measure from the following:
1. 12-item short form health survey (SF-12)
2. Health Utilities Index mark 2 and mark 3 (HUI 2/3)
Administered for self-report, postal questionnaire at baseline, three and six month follow-up.
Secondary outcome measure(s) 1. The Chronic Pain Grade (assessing severity of pain)
2. The Hospital Anxiety and Depression Scale (assessing level of anxiety and depression)
Questionnaires are administered as self-report, postal questionnaire at baseline, three and six month follow-up.
Sources of funding Medical Research Council (MRC) (UK) (ref: G0701769)
Trial website
Publications
Contact name Prof  Christine  Bond
  Address Centre of Academic Primary Care
Foresterhill Health Centre
Westburn Road
  City/town Aberdeen
  Zip/Postcode AB25 2AY
  Country United Kingdom
Sponsor University of Aberdeen (UK)
  Address c/o Dr Elizabeth Rattray
Deputy Director
Research and Innovation
King's College
  City/town Aberdeen
  Zip/Postcode AB24 3FX
  Country United Kingdom
  Sponsor website: http://www.abdn.ac.uk/
Date applied 11/12/2009
Last edited 29/01/2010
Date ISRCTN assigned 29/01/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central